Es Rtcgm Adip Vs Mdis Smbg T1d

---
name: es-rtcgm-adip-vs-mdis-smbg-t1d
description: This skill suggests using real-time continuous glucose monitoring (CGM) and algorithm-driven insulin pumps (ADIPs) rather than multiple daily injections (MDIs) with self-monitoring of blood glucose (SMBG) three or more times daily for adults and children with type 1 diabetes (T1D). Trigger phrases include "Should I use RT-CGM+ADIP or MDI+SMBG for this T1D patient?" or "Is intensive pump therapy indicated for this patient?"
---

# RT-CGM+ADIPs vs MDIs+SMBG for Type 1 Diabetes

## STEP 1 — Gather Information
Confirm T1D diagnosis, current MDI+SMBG regimen (≥3 checks/day), age, hypoglycemia history, impaired awareness, patient tech readiness, and insurance/device access.

## STEP 2 — Rule In / Rule Out
Is the patient with T1D using MDI with SMBG three or more times daily? If yes, proceed; if no, consider alternative glucose monitoring/insulin strategies.

## STEP 3 — Classify or Stratify
Stratify by hypoglycemia risk: high (prior severe episodes or impaired awareness) vs lower risk. High-risk patients benefit most; lower-risk patients still considered based on preference and access.

## STEP 4 — Decide
For qualifying patients, prescribe RT-CGM+ADIP with structured education; retain SMBG for calibration/confirmation; schedule follow‑up to assess TIR, hypoglycemia, and device tolerance.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on CGM without confirmatory SMBG; avoid in patients unable to respond to alerts or manage device wear; do not overlook cost/coverage barriers; never skip diabetes education on device use and hypoglycemia prevention.

## Concrete Clinical Example
A 12‑year‑old with T1D on MDI+SMBG 4×/day reports nocturnal hypoglycemia and impaired awareness. After confirming eligibility, RT‑CGM+ADIP is started with training; SMBG used twice daily for calibration. At 3‑month review, TIR improves from 55% to 70% and severe hypoglycemia events drop from 2/month to 0.

**Source:** Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596